PMID- 35956122
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220815
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 15
DP  - 2022 Aug 2
TI  - Perceptions about the Management of Patients with DM2 and COVID-19 in the 
      Hospital Care Setting.
LID - 10.3390/jcm11154507 [doi]
LID - 4507
AB  - BACKGROUND: COVID-19 entails a higher rate of complications in subjects with type 
      2 diabetes mellitus (T2DM). Likewise, COVID-19 infection can cause alterations in 
      glucose metabolism that may lead to worse control. The aim of the study was to 
      analyse the perceptions of a large group of Spanish physicians about the 
      relationship between COVID-19 and T2DM, as well as the management, monitoring, 
      and treatment of both diseases. METHODS: A cross-sectional multicenter national 
      project was conducted based on a survey which included opinion, attitude, and 
      behavior (OAB) questions. Physicians specialised in internal medicine or 
      endocrinology, whose usual clinical practices included the management of T2DM, 
      responded to the survey between March and April 2021. RESULTS: A total of 112 
      participants responded to the survey, from which 64.3% believed that COVID-19 
      entailed a higher risk of glycaemic decompensation irrespective of the presence 
      of previously known T2DM. Obesity was considered a risk factor for poor control 
      of T2DM by 57.7% and for a worse course of COVID-19 by 61.0%. Treatment 
      intensification in not-on-target patients was considered by 57.1% in the presence 
      of COVID-19 and by 73.2% in the absence of COVID-19. No participants considered 
      the suspension of dipeptidyl peptidase 4 inhibitors (DPP-4i) in ambulatory 
      patients, 85.7% declared that this therapeutic approach in hospitalized patients 
      should be kept, and 88.4% supported the option of maintaining DPP-4i when 
      corticosteroids were prescribed. CONCLUSION: The physicians involved in the 
      management of T2DM and COVID-19 are aware of the bidirectional relationship 
      between both conditions. However, the monitoring and therapeutic management of 
      patients with T2DM who are infected by SARS-CoV-2 needs improvement through the 
      following of the current recommendations and available evidence.
FAU - Gomez-Huelgas, Ricardo
AU  - Gomez-Huelgas R
AUID- ORCID: 0000-0002-9909-3555
AD  - Servicio de Medicina Interna, Hospital Regional Universitario, Instituto de 
      Investigacion Biomedica de Malaga (IBIMA), Universidad de Malaga (UMA), 29010 
      Malaga, Spain.
FAU - Gomez-Peralta, Fernando
AU  - Gomez-Peralta F
AD  - Unidad de Endocrinologia y Nutricion, Hospital General, Calle Luis Erik Claveria 
      Neurologo S/N, 40002 Segovia, Spain.
LA  - eng
GR  - no number/laboratorios Esteve/
PT  - Journal Article
DEP - 20220802
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC9369585
OTO - NOTNLM
OT  - ambulatory care
OT  - comorbidity
OT  - coronavirus infections
OT  - diabetes complications
OT  - diabetes mellitus
OT  - hospitalization
OT  - hypoglycemic agents
OT  - type 2
COIS- Ricardo Gomez-Huelgas has provided consultancy services and has served as a 
      speaker and has participated as a researcher in studies financed by Boehringer 
      Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Astra Zeneca, MSD, Janssen, or 
      Esteve. Fernando Gomez-Peralta has provided consulting services for Abbott, Astra 
      Zeneca, Esteve, Novartis, Novo Nordisk, and Sanofi and has participated as an 
      investigator in studies funded by Boehringer Ingelheim, Eli Lilly, Novo Nordisk, 
      and Sanofi; he has served as a speaker for Abbott, Astra Zeneca, Boehringer 
      Ingelheim, Bristol Myers Squibb, Eli Lilly, Esteve, Novartis, Novo Nordisk, and 
      Sanofi. The funders had no role in the design of the study; in the collection, 
      analyses, or interpretation of data; in the writing of the manuscript; or in the 
      decision to publish the results.
EDAT- 2022/08/13 06:00
MHDA- 2022/08/13 06:01
PMCR- 2022/08/02
CRDT- 2022/08/12 01:15
PHST- 2022/06/29 00:00 [received]
PHST- 2022/07/20 00:00 [revised]
PHST- 2022/07/30 00:00 [accepted]
PHST- 2022/08/12 01:15 [entrez]
PHST- 2022/08/13 06:00 [pubmed]
PHST- 2022/08/13 06:01 [medline]
PHST- 2022/08/02 00:00 [pmc-release]
AID - jcm11154507 [pii]
AID - jcm-11-04507 [pii]
AID - 10.3390/jcm11154507 [doi]
PST - epublish
SO  - J Clin Med. 2022 Aug 2;11(15):4507. doi: 10.3390/jcm11154507.